ERNAW NASDAQ
Ernexa Therapeutics Inc. Warrants
1W: +52.5%
1M: +357.4%
YTD: +60.1%
$0.14
-0.03 (-15.68%)
Weekly Expected Move ±99.0%
$-0
$0
$0
$0
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$1.1M
52W Range0.121-0.1525
Volume106,447
Avg Volume42,712
Beta1.89
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOSanjeev Luther
Employees6
SectorFinancial Services
IndustryAsset Management
IPO Date2024-07-12
Websiteernexatx.com
1035 Cambridge Street
Cambridge, MA 02141
US
Cambridge, MA 02141
US
212 582 1199
About Ernexa Therapeutics Inc. Warrants
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Recent Insider Trades
No insider trades found